Aytu Biopharma annual operating income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aytu Biopharma Operating Income Growth & History (AYTU)
Aytu Biopharma's operating income was −$7.8M for fiscal 2025.
View full Aytu Biopharma company overviewAytu Biopharma annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | −$7.8M | −$6.2M | — |
| 2024 | 2024-06-30 | −$1.6M | $15.5M | — |
| 2023 | 2023-06-30 | −$17.1M | $92.8M | — |
| 2022 | 2022-06-30 | −$109.9M | −$51.0M | — |
| 2021 | 2021-06-30 | −$58.9M | −$37.7M | — |
| 2020 | 2020-06-30 | −$21.1M | −$4.3M | — |
| 2019 | 2019-06-30 | −$16.8M | $2.9M | — |
| 2018 | 2018-06-30 | −$19.7M | $425,002 | — |
| 2017 | 2017-06-30 | −$20.1M | $1.6M | — |
| 2016 | 2016-06-30 | −$21.7M | −$14.1M | — |
| 2015 | 2015-06-30 | −$7.6M | −$1.3M | — |
| 2014 | 2014-06-30 | −$6.3M | — | — |
| 2013 | 2013-08-31 | −$52,414 | $3,942 | — |
| 2012 | 2012-08-31 | −$56,356 | $77,263 | — |
| 2011 | 2011-08-31 | −$133,619 | — | — |
Aytu Biopharma quarterly operating income
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q2.14
Q3.14
Q1.15
Q2.15
Q2.15
Q3.15
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Operating income | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | −$4.1M | −$6.5M | — |
| Q2 2026 | 2025-12-31 | −$2.0M | −$275,000 | — |
| Q1 2026 | 2025-09-30 | −$1.5M | −$574,000 | — |
| Q4 2025 | 2025-06-30 | −$7.6M | −$5.3M | — |
| Q3 2025 | 2025-03-31 | $2.4M | $4.0M | — |
| Q2 2025 | 2024-12-31 | −$1.7M | −$4.8M | — |
| Q1 2025 | 2024-09-30 | −$930,000 | −$63,000 | — |
| Q4 2024 | 2024-06-30 | −$2.3M | −$2.4M | — |
| Q3 2024 | 2024-03-31 | −$1.6M | $7.0M | — |
| Q2 2024 | 2023-12-31 | $3.1M | $10.0M | — |
| Q1 2024 | 2023-09-30 | −$867,000 | $941,000 | — |
| Q4 2023 | 2023-06-30 | $169,000 | $17.7M | — |
| Q3 2023 | 2023-03-31 | −$8.6M | $44.9M | — |
| Q2 2023 | 2022-12-31 | −$6.9M | $4.4M | — |
| Q1 2023 | 2022-09-30 | −$1.8M | $25.9M | — |
| Q4 2022 | 2022-06-30 | −$17.5M | $6.6M | — |
| Q3 2022 | 2022-03-31 | −$53.4M | −$27.8M | — |
| Q2 2022 | 2021-12-31 | −$11.3M | −$5.7M | — |
| Q1 2022 | 2021-09-30 | −$27.7M | −$24.1M | — |
| Q4 2021 | 2021-06-30 | −$24.1M | −$17.4M | — |
| Q3 2021 | 2021-03-31 | −$25.7M | −$20.9M | — |
| Q2 2021 | 2020-12-31 | −$5.6M | −$607,905 | — |
| Q1 2021 | 2020-09-30 | −$3.6M | $1.2M | — |
| Q4 2020 | 2020-06-30 | −$6.6M | −$2.1M | — |
| Q3 2020 | 2020-03-31 | −$4.8M | −$494,805 | — |
| Q2 2020 | 2019-12-31 | −$5.0M | −$416,365 | — |
| Q1 2020 | 2019-09-30 | −$4.7M | −$1.3M | — |
| Q4 2019 | 2019-06-30 | −$4.6M | −$754,362 | — |
| Q3 2019 | 2019-03-31 | −$4.3M | $3.2M | — |
| Q2 2019 | 2018-12-31 | −$4.6M | −$556,782 | — |
| Q1 2019 | 2018-09-30 | −$3.4M | $938,757 | — |
| Q4 2018 | 2018-06-30 | −$3.8M | $1.3M | — |
| Q3 2018 | 2018-03-31 | −$7.5M | −$2.7M | — |
| Q2 2018 | 2017-12-31 | −$4.0M | $204,746 | — |
| Q1 2018 | 2017-09-30 | −$4.4M | $1.6M | — |
| Q4 2017 | 2017-06-30 | −$5.1M | $8.2M | — |
| Q3 2017 | 2017-03-31 | −$4.9M | −$1.6M | — |
| Q2 2017 | 2016-12-31 | −$4.2M | −$1.2M | — |
| Q1 2017 | 2016-09-30 | −$6.0M | −$3.8M | — |
| Q4 2016 | 2016-06-30 | −$13.3M | — | — |
| Q3 2016 | 2016-03-31 | −$3.2M | −$1.4M | — |
| Q2 2016 | 2015-12-31 | −$3.0M | −$1.4M | — |
| Q1 2016 | 2015-09-30 | −$2.2M | −$71,394 | — |
| Q3 2015 · Mar 31 | 2015-03-31 | −$1.8M | $184,829 | — |
| Q3 2015 · Feb 28 | 2015-02-28 | −$9,401 | $11,158 | — |
| Q2 2015 · Dec 31 | 2014-12-31 | −$1.6M | — | — |
| Q2 2015 · Nov 30 | 2014-11-30 | −$15,291 | −$284 | — |
| Q1 2015 | 2014-09-30 | −$2.1M | — | — |
| Q3 2014 | 2014-05-31 | −$11,132 | $826 | — |
| Q2 2014 · Mar 31 | 2014-03-31 | −$2.0M | — | — |
| Q2 2014 · Feb 28 | 2014-02-28 | −$20,559 | −$8,008 | — |
| Q1 2014 | 2013-11-30 | −$15,007 | $3,826 | — |
| Q4 2013 | 2013-08-31 | −$9,072 | — | — |
| Q3 2013 | 2013-05-31 | −$11,958 | −$873 | — |
| Q2 2013 | 2013-02-28 | −$12,551 | — | — |
| Q1 2013 | 2012-11-30 | −$18,833 | $43 | — |
| Q3 2012 | 2012-05-31 | −$11,085 | $8,936 | — |
| Q2 2012 · Feb 29 | 2012-02-29 | −$9,223 | $17,090 | — |
| Q2 2012 · Feb 28 | 2012-02-28 | −$9,223 | $17,090 | — |
| Q1 2012 | 2011-11-30 | −$18,876 | −$2,325 | — |
| Q4 2011 | 2011-08-31 | −$70,734 | — | — |
| Q3 2011 | 2011-05-31 | −$20,021 | — | — |
| Q2 2011 | 2011-02-28 | −$26,313 | — | — |
| Q1 2011 | 2010-11-30 | −$16,551 | — | — |
Aytu Biopharma operating income trends
Over the last five fiscal years, Aytu Biopharma's operating income increased from −$21.1M to −$7.8M, a change of $13.3M. The latest reported quarter, Q3 2026, shows −$4.1M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
SEC-reported operating income
TickerStat standardizes operating income reported in company SEC filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aytu Biopharma source filings ↗